Adjuvant TNF-α therapy to electrochemotherapy with intravenous cisplatin in murine sarcoma exerts synergistic antitumor effectiveness

1. Marty M, Sersa G, Garbay J, Gehl J, Collins C, Snoj M, et al. Electrochemo therapy - An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 2006; 4: 3-13.10.1016/j.ejcsup.2006.08.002Search in Google Scholar

2. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of ele ctrochemotherapy: A systematic review and meta-analysis. EJSO 2013; 39: 4-16.10.1016/j.ejso.2012.08.01622980492Search in Google Scholar

3. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, et al. Electrochemotherapy for cutaneous and subcutaneous tumor lesions: A novel therapeutic approach. Dermatol Ther 2010; 23: 651-61.10.1111/j.1529-8019.2010.01370.x21054709Search in Google Scholar

4. Soden DM, Larkin JO, Collins CG, Tangney M, Aarons S, Piggott J, et al. Succ essful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours. Cancer Lett 2006; 232: 300-10.10.1016/j.canlet.2005.03.05715964138Search in Google Scholar

5. Mahmood F, Gehl J. Optimizing clinical performance and geometrical robustnes s of a new electrode device for intracranial tumor electroporation. Bioelectrochem 2011; 81: 10-6.10.1016/j.bioelechem.2010.12.00221256816Search in Google Scholar

6. Agerholm-Larsen B, Iversen HK, Ibsen P, Moller JM, Mahmood F, Jensen KS, et al. Preclinical validation of electrochemotherapy as an effective treatment for brain tumors. Cancer Res 2011; 71: 3753-62.10.1158/0008-5472.CAN-11-045121507935Search in Google Scholar

7. Edhemovic I, Gadzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A, et al. E lectrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res T 2011; 10: 475-85.10.7785/tcrt.2012.500224452741421895032Search in Google Scholar

8. Linnert M, Iversen HK, Gehl J. Multiple brain metastases - current managemen t and perspectives for treatment with electrochemotherapy. Radiol Oncol 2012; 46: 271-8.10.2478/v10019-012-0042-y357289423412694Search in Google Scholar

9. Fini M, Salamanna F, Parrilli A, Martini L, Cadossi M, Maglio M, et al. Elec trochemotherapy is effective in the treatment of rat bone metastases. Clin Exp Metastasis 2013; 30: 1033-45.10.1007/s10585-013-9601-x23832763Search in Google Scholar

10. Fini M, Tschon M, Ronchetti M, Cavani F, Bianchi G, Mercuri M, et al. Ablat ion of bone cells by electroporation. J Bone Joint Surg BR 2010; 92: 1614-20.10.1302/0301-620X.92B11.2466421037363Search in Google Scholar

11. Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B, et a l. Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol 2014; 110: 320-7.10.1002/jso.23625Search in Google Scholar

12. Sersa G, Stabuc B, Cemazar M, Jancar B, Miklavcic D, Rudolf Z. Electrochemo therapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients. Eur J Cancer 1998; 34: 1213-8.10.1016/S0959-8049(98)00025-2Search in Google Scholar

13. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy wi th cisplatin: The systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 2000; 10: 381-85.10.1097/00008390-200008000-0001010985673Search in Google Scholar

14. Cemazar M, Miklavcic D, Vodovnik L, Jarm T, Rudolf Z, Stabuc B, et al. Impr oved therapeutic effect of electrochemotherapy with cisplatin by intratumoral drug administration and changing of electrode orientation for electropermeabilization on EAT tumors in mice. Radiol Oncol 1995; 29: 121-27.Search in Google Scholar

15. Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electroche motherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 2010; 10: 729-46.10.1586/era.10.4320470005Search in Google Scholar

16. Calvet CY, Famin D, Andre FM, Mir LM. Electrochemotherapy with bleomycin in duces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology 2014; 3: e28131.10.4161/onci.28131411194025083316Search in Google Scholar

17. Goetz FW, Planas JV, MacKenzie S. Tumor necrosis factors. Dev Comp Immunol 2004; 28: 487-97.10.1016/j.dci.2003.09.00815062645Search in Google Scholar

18. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth F R 2005; 16: 35-53.10.1016/j.cytogfr.2004.11.00115733831Search in Google Scholar

19. Cemazar M, Miklavcic D, Scancar J, Dolzan V, Golouh R, Sersa G. Increased p latinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin. Brit J Cancer 1999; 79: 1386-91.10.1038/sj.bjc.6690222237426410188880Search in Google Scholar

20. Campana LG, Mali B, Sersa G, Valpione S, Giorgi CA, Strojan P, et al. Elect rochemotherapy in non-melanoma head and neck cancers: a retrospective analysis of the treated cases. Br J Oral Maxillofac Surg 2014; 52: 957-64.10.1016/j.bjoms.2014.08.00425183266Search in Google Scholar

21. Campana LG, Valpione S, Falci C, Mocellin S, Basso M, Corti L, et al. The a ctivity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study. Breast Cancer Res Tr 2012; 134: 1169-78.10.1007/s10549-012-2095-422821399Search in Google Scholar

22. Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V , et al. Bleomycin-based electrochemotherapy: Clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol 2009; 16: 191-99.10.1245/s10434-008-0204-8Search in Google Scholar

23. Campana LG, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Brit J Surg 2012; 99: 821-30.10.1002/bjs.8749Search in Google Scholar

24. Mali B, Miklavcic D, Campana LG, Cemazar M, Sersa G, Snoj M, et al. Tumor s ize and effectiveness of electrochemotherapy. Radiol Oncol 2013; 47: 32-41.10.2478/raon-2013-0002Search in Google Scholar

25. Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Rissone M, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008; 15: 2215-22.10.1245/s10434-008-9976-0Search in Google Scholar

26. Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M, et al. Pote ntiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radiol Oncol 2012; 46: 302-11.10.2478/v10019-012-0044-9Search in Google Scholar

27. Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R. In vivo electrop oration of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 2000; 10: 577-83.10.1097/00008390-200012000-00010Search in Google Scholar

28. Torrero MN, Henk WG, Li S. Regression of high-grade malignancy in mice by b leomycin and interleukin-12 electrochemogenetherapy. Clin Cancer Res 2006; 12: 257-63.10.1158/1078-0432.CCR-05-1514Search in Google Scholar

29. Ramirez LH, Orlowski S, An D, Bindoula G, Dzodic R, Ardouin P, et al. Elect rochemotherapy on liver tumours in rabbits. Brit J Cancer 1998; 77: 2104-11.10.1038/bjc.1998.354Search in Google Scholar

30. Sersa G, Cemazar M, Menart V, Gaberc-Porekar V, Miklavcic D. Anti-tumor eff ectiveness of electrochemotherapy with bleomycin is increased by TNFalpha on SA-1 tumors in mice. Cancer Lett 1997; 116: 85-92.10.1016/S0304-3835(97)00170-5Search in Google Scholar

31. Roberts NJ, Zhou S, Diaz LA, Jr., Holdhoff M. Systemic use of tumor necrosi s factor alpha as an anticancer agent. Oncotarget 2011; 2: 739-51.10.18632/oncotarget.344324815922036896Search in Google Scholar

32. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-71.10.1038/nrc262819343034Search in Google Scholar

33. Eisenthal A, Schwartz I, Issakov J, Klausner Y, Misonzhnik F, Lifschitz-Mer cer B. Immunohistochemistry evaluation of the effect in vivo of tumor necrosis factor (TNF)-alpha on blood vessel density in murine fibrosarcoma. Sarcoma 2003; 7: 57-61.10.1080/13577140310001607275239552218521369Search in Google Scholar

34. Nooijen PT, Manusama ER, Eggermont AM, Schalkwijk L, Stavast J, Marquet RL, et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Brit J Cancer 1996; 74: 1908-15.10.1038/bjc.1996.65220748228980389Search in Google Scholar

35. Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Brit J Cancer 1996; 74: 533-6.10.1038/bjc.1996.39720746658761366Search in Google Scholar

36. Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human T NF in human cancer therapy. Cancer Immunity 2006; 6: 6.Search in Google Scholar

37. Menon C, Ghartey A, Canter R, Feldman M, Fraker DL. Tumor necrosis factor- a lpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann Surg 2006; 244: 781-91.10.1097/01.sla.0000231723.81218.72185660317060772Search in Google Scholar

38. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: m olecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11: 397-408.10.1634/theoncologist.11-4-39716614236Search in Google Scholar

39. Folli S, Pelegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, et al. Tum ornecrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993; 53: 829-36.10.1002/ijc.29105305218449608Search in Google Scholar

40. de Wilt JHW, ten Hagen TLM, de Boeck G, van Tiel ST, de Bruijn EA, Eggermon t AMM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Brit J Cancer 2000; 82: 1000-3.10.1054/bjoc.1999.1032237442010737379Search in Google Scholar

41. Sersa G, Willingham V, Milas L. Anti-Tumor Effects of Tumor Necrosis Factor Alone or Combined with Radiotherapy. Int J Cancer 1988; 42: 129-34.10.1002/ijc.29104201243391701Search in Google Scholar